Multiple Myeloma
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
J&J launches campaign to raise awareness and support for multiple myeloma patients and caregivers
Johnson & Johnson’s multiple myeloma division is embarking on an initiative dubbed “Make It HAPPen,” aimed at bolstering support for ...
AbbVie drops option on Harpoon’s BCMA TriTAC for multiple myeloma
AbbVie has decided against pursuing its option on Harpoon Therapeutics’ anti-BCMA T-cell engager HPN217, thus avoiding a $200 million payment ...
FDA approves Aphexda for stem cell mobilization in multiple myeloma
After a decade of limited progress, the FDA has granted approval for the use of BioLineRx’s motixafortide, also known as ...
BMS faces lawsuit for allegedly extending Pomalyst monopoly with fraudulent patents and payoffs
Bristol Myers Squibb (BMS) and Celgene’s widely-used multiple myeloma treatment, Pomalyst, has found itself entangled in a legal battle after ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
Unveiling 2023’s Drug Approvals: Beyond Oncology Boundaries
In the ever-evolving realm of oncology of 2023 emerges as a pivotal era characterized by a wave of significant approvals ...
CAR T-Cell Therapy in Hematological Malignancies: A Breakthrough or a Bust?
Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes. They include leukemia, lymphoma, and multiple myeloma. ...
Janssen’s Bispecific Antibody Tecvayli Receives European Commission Approval for Reduced Dosing Frequency
The Janssen Pharmaceutical Companies of Johnson & Johnson have proudly unveiled a significant advancement in cancer treatment. The European Commission ...
Carvykti CAR-T Therapy by J&J and Legend Biotech Persists Amid New Bispecific
Johnson & Johnson and Legend Biotech’s Carvykti maintains growth in the multiple myeloma market despite the emergence of a more ...
Pfizer’s Elrexfio Gets FDA Nod, Ignites Showdown with J&J in Multiple Myeloma Arena
Pfizer’s latest BCMA-targeted drug, Elrexfio (elranatamab), has gained FDA approval for treating multiple myeloma patients who have undergone at least ...
Johnson & Johnson Takes Lead in Bispecific Antibody Approval for Multiple Myeloma, Leaving Pfizer in the Dust
The FDA has granted accelerated approval to talquetamab-tgvs, branded as Talvey, for treating relapsed or refractory multiple myeloma in adults ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
Bispecific Antibodies in Multiple Myeloma: A Combination Leads to Durable Responses
Bispecific antibodies in multiple myeloma are a new class of drugs that can target two different antigens at the same ...
Darzalex Continues Rising Trend – J&J Boosts Projected Yearly Revenues by $1 Billion
In 2017, Genmab CEO Jan van de Winkel envisioned that the multiple myeloma drug Darzalex, marketed by Johnson & Johnson, ...
Multiple Myeloma: What You Need to Know About the Latest Advances
Multiple myeloma is a type of blood cancer that affects plasma cells, which are responsible for producing antibodies that help ...
How BCMA-targeted therapies are changing the game for multiple myeloma
Imagine a world where you could treat cancer with a simple injection or infusion, without the need for surgery, chemotherapy, ...
FDA-Approved Medications for Multiple Myeloma: What You Need to Know
Let’s find out FDA-approved medications for multiple myeloma. Multiple myeloma is a type of blood cancer that affects plasma cells, ...
Daratumumab in Multiple Myeloma: What You Need to Know
Multiple myeloma is a serious and incurable blood cancer that affects millions of people worldwide. But there is hope. A ...
Third Line Treatment For Multiple Myeloma: What You Need to Know
Multiple myeloma is a type of blood cancer that affects plasma cells, which are responsible for producing antibodies. When plasma ...
Second-line treatment of multiple myeloma: current choices and future prospects
This blog will discuss the second-line treatment of multiple myeloma, a blood cancer that affects antibody-producing plasma cells. Multiple myeloma ...
First-Line Treatment of Multiple Myeloma: What You Need to Know
Multiple myeloma is a type of blood cancer that affects plasma cells, which are responsible for producing antibodies. It is ...
Multiple Myeloma: What You Need to Know About This Rare Blood Cancer
Imagine having a type of white blood cell that is supposed to protect you from infections, but instead turns against ...
FDA Approves Cyclophosphamide Injection NDA for Multiple Cancers
Source – Nevakar Injectables On July 3, 2023 the FDA has approved a new drug application (NDA) for 200-mg/mL vials ...
Clinical Activity Is Provoked by Teclistamab Triplet in R/R Multiple Myeloma
The Phase Ib (NCT04722146) MajesTEC-2 trial demonstrated promising clinical activity in patients with relapsed/refractory multiple myeloma (RRMM) when combining teclistamab ...
The Impact of CD38 Multiple Myeloma Treatment: A Comprehensive Analysis
Introduction The landscape of multiple myeloma treatment has witnessed a significant breakthrough with the advent of CD38 Multiple Myeloma Treatment ...
